| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | COL8A1 |
| Uniprot No | P27658 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 572-744aa |
| 氨基酸序列 | AVMPPTPPPQGEYLPDMGLGIDGVKPPHAYGAKKGKNGGPAYEMPAFTAELTAPFPPVGAPVKFNKLLYNGRQNYNPQTGIFTCEVPGVYYFAYHVHCKGGNVWVALFKNNEPVMYTYDEYKKGFLDQASGSAVLLLRPGDRVFLQMPSEQAAGLYAGQYVHSSFSGYLLYPM |
| 预测分子量 | 31.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于COL8A1重组蛋白的3篇参考文献示例(注：文献为示例性内容，实际引用请通过学术数据库核实)：
---
1. **文献名称**: "Recombinant COL8A1 Enhances Corneal Endothelial Cell Adhesion and Wound Healing in Vitro"
**作者**: Smith A, et al.
**摘要**: 研究利用重组COL8A1蛋白处理体外培养的角膜内皮细胞，发现其通过激活整合素β1信号通路，显著促进细胞黏附和损伤修复，为角膜内皮功能障碍的治疗提供潜在策略。
2. **文献名称**: "Functional Role of Recombinant COL8A1 in Tumor Angiogenesis: Implications for Metastatic Microenvironment"
**作者**: Johnson B, et al.
**摘要**: 通过哺乳动物细胞表达系统制备重组COL8A1蛋白，发现其能诱导内皮细胞迁移和血管样结构形成，并证实其在肿瘤微环境中通过调节VEGF通路促进血管生成。
3. **文献名称**: "Structural and Biophysical Analysis of Recombinant Human COL8A1 Collagen Domains"
**作者**: Lee C, et al.
**摘要**: 利用大肠杆菌系统表达并纯化COL8A1的NC1结构域重组蛋白，结合X射线晶体学分析其三维结构，揭示其与细胞外基质蛋白相互作用的分子机制。
---
如需具体文献，建议通过PubMed或Google Scholar检索关键词“COL8A1 recombinant protein”或“COL8A1 expression”获取最新研究。
COL8A1 recombinant protein is derived from the human COL8A1 gene, which encodes the alpha-1 chain of type VIII collagen, a short-chain collagen belonging to the collagen family. Unlike classical fibrillar collagens, type VIII collagen forms a hexagonal network structure and is categorized as a multiplexin due to its multiple triple-helix domains and interruptions. The COL8A1 chain contains three distinct domains: a short N-terminal non-collagenous region, a central collagenous repeat domain rich in Gly-X-Y amino acid motifs, and a C-terminal non-collagenous domain. It assembles into homotrimers or heterotrimers with the alpha-2 chain (COL8A2), contributing to basement membranes, vascular endothelium, and corneal tissues.
Biologically, COL8A1 plays roles in cell adhesion, migration, and tissue remodeling. It is implicated in angiogenesis, wound healing, and maintaining structural integrity in tissues like the cornea and blood vessels. Dysregulation of COL8A1 has been linked to pathologies such as Fuchs' endothelial corneal dystrophy (FECD), atherosclerosis, and tumor progression, where abnormal extracellular matrix (ECM) deposition occurs.
Recombinant COL8A1 protein is typically produced in mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, including hydroxylation and triple-helix formation. Purification often involves affinity tags (e.g., His-tag) and chromatography techniques. This protein serves as a critical tool for studying collagen VIII's interactions with ECM components (e.g., integrins, laminins), signaling pathways in endothelial or epithelial cells, and disease mechanisms. Researchers also utilize it to develop therapeutic strategies targeting collagen VIII-related disorders or to engineer biomimetic scaffolds in regenerative medicine. Its applications extend to drug screening and antibody production for diagnostic assays.
×
